Sanofi is evaluating a potential acquisition of Insmed, the United States respiratory drugmaker, according to a Bloomberg report published November 19 and cited by Fierce Pharma, BioSpace and Pharmaceutical Executive. The French company is working with advisers on a deal that could be valued between $35 billion and $43 billion. Neither company has commented, the talks are described as preliminary, and Sanofi could decide against an offer or face rival bidders.
The target’s asset is Brinsupri, a treatment for non cystic fibrosis bronchiectasis approved in August 2025. Insmed reported a little over $917 million in global Brinsupri sales over the first nine months of 2026 and expects full year Brinsupri revenue of $1.35 billion to $1.4 billion, within total company revenue guidance of $1.8 billion to $1.9 billion. Its second product, Arikayce, posted $124 million in third quarter sales. Insmed shares rose about 18 percent to $141.87 on the report, and closed Thursday at $144, while Sanofi shares slipped about 2 percent to $46.15.
The strategic logic is Sanofi’s dependence on Dupixent, whose patent expires in the early 2030s, and a run of pipeline setbacks under new chief executive Belen Garijo. Analysts at BMO Capital Markets called the fit clear, adding Insmed’s respiratory growth to Sanofi’s commercial infrastructure, and William Blair pointed to Sanofi’s recent Dupixent approval push in COPD. Both banks also flagged price: a deal in the $40 billion range against net debt of about 12 billion euros is the central obstacle, and it would be the largest pharma transaction since Pfizer’s $43 billion Seagen acquisition in 2023.
Treat this as a reported intention, not a deal. There is no agreement, no offer and no company confirmation, and Sanofi’s finance chief said in October that a major transaction in the next couple of months was unlikely, even as the company promised more on its priorities by year end.